螞蟻集團旗下花唄及借唄兩個ABS項目獲上交所通過 規模共200億人幣
《路透》報道,上交所債券項目信息平台顯示,螞蟻集團旗下花唄、借唄兩個資產支持證券(ABS)項目獲通過,合計規模200億元人民幣(下同),同時另有三個總計260億元的ABS項目處於已受理狀態。
是次獲通過的ABS分別是中信證券花唄一至十期授信付款資產支持專項計劃,及國泰君安借唄第4至12期消費貸款資產支持專項計劃,規模均為100億元。
至於已受理ABS目分別為天弘創新花唄第8至15期消費授信融資資產支持專項計劃、財通資管花唄授信付款資產支持專項計劃,和中信證券借唄五至十四期消費貸款資產支持專項計劃。規模分別80億元、80億元和100億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.